glp-1 therapy thibodaux Weight Loss in Santee, SC Access to GLP-1 weight loss

Once-weekly semaglutide doubles the five-year risk of nonarteritic anterior ischemic optic neuropathy in a Danish cohort of 424,152 persons with type 2 diabetes

The SURMOUNT-1 study was a placebo-controlled 72-week trial in obese subjects that randomized 2,539 participants without diabetes into four equally large study arms with placebo or one of the three tirzepatide doses (5, 10, or 15 mg once weekly)

This vastly exceeded the 14.9% average weight loss with semaglutide 2.4 mg weekly in the STEP-1 trial

Liraglutide and Semaglutide are both GLP1R single-target agonists developed by Novo Nordisk

doi: 10.3892/mmr.2017.6321

The PlexusDx Precision Peptide Genetic Test analyzes variants in GLP1R, GIPR, FTO, and MC4R genes plus 10 additional pathways to predict how your body responds to semaglutide and tirzepatide